IRIS
GROSSI, Laurino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.241
EU - Europa 5.236
AS - Asia 5.008
SA - Sud America 526
AF - Africa 54
Continente sconosciuto - Info sul continente non disponibili 22
OC - Oceania 5
Totale 18.092
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.154
SG - Singapore 1.929
CN - Cina 1.455
UA - Ucraina 821
IT - Italia 819
IE - Irlanda 729
TR - Turchia 582
RU - Federazione Russa 578
SE - Svezia 565
GB - Regno Unito 540
FR - Francia 431
BR - Brasile 420
VN - Vietnam 402
IN - India 379
DE - Germania 320
FI - Finlandia 180
AT - Austria 65
PL - Polonia 56
HK - Hong Kong 44
CA - Canada 40
MX - Messico 38
AR - Argentina 36
BD - Bangladesh 34
IQ - Iraq 33
NL - Olanda 28
EC - Ecuador 27
JP - Giappone 21
KR - Corea 21
EU - Europa 20
BE - Belgio 18
ZA - Sudafrica 17
ES - Italia 16
ID - Indonesia 16
RO - Romania 16
CO - Colombia 11
LT - Lituania 11
MA - Marocco 11
PK - Pakistan 11
IL - Israele 10
CL - Cile 8
JO - Giordania 8
KE - Kenya 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 7
PE - Perù 7
PY - Paraguay 7
SA - Arabia Saudita 7
CZ - Repubblica Ceca 6
GR - Grecia 6
PS - Palestinian Territory 5
TW - Taiwan 5
AL - Albania 4
AU - Australia 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
DZ - Algeria 4
EG - Egitto 4
IR - Iran 4
PH - Filippine 4
VE - Venezuela 4
CH - Svizzera 3
EE - Estonia 3
ET - Etiopia 3
HU - Ungheria 3
MY - Malesia 3
NO - Norvegia 3
OM - Oman 3
UY - Uruguay 3
BG - Bulgaria 2
BH - Bahrain 2
BO - Bolivia 2
CI - Costa d'Avorio 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
KZ - Kazakistan 2
LB - Libano 2
LU - Lussemburgo 2
PA - Panama 2
SY - Repubblica araba siriana 2
AP - ???statistics.table.value.countryCode.AP??? 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CG - Congo 1
GE - Georgia 1
GT - Guatemala 1
KH - Cambogia 1
LV - Lettonia 1
MD - Moldavia 1
MU - Mauritius 1
NP - Nepal 1
PT - Portogallo 1
PW - Palau 1
RE - Reunion 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SR - Suriname 1
SV - El Salvador 1
TH - Thailandia 1
TN - Tunisia 1
Totale 18.090
Salva come PNG Salva come JPEG
Città #
Singapore 1.303
Jacksonville 943
Chandler 779
San Jose 738
Dublin 721
Dearborn 468
Ashburn 388
Southend 378
Princeton 354
Beijing 334
Dallas 303
Nanjing 284
Izmir 272
Wilmington 254
Los Angeles 204
Cambridge 157
Ho Chi Minh City 130
Woodbridge 119
Buffalo 118
Ann Arbor 115
Santa Clara 111
Tongling 104
New York 94
Nanchang 93
The Dalles 93
Hanoi 88
Council Bluffs 86
Boardman 66
Houston 65
Moscow 57
Hefei 56
Hebei 53
Vienna 52
Shenyang 48
Altamura 47
Munich 47
São Paulo 47
Redondo Beach 46
Rome 46
Kunming 45
Tianjin 43
Jiaxing 40
Kraków 35
Pescara 35
Hong Kong 34
Chieti 29
Hangzhou 28
Bologna 25
Brooklyn 25
Norwalk 25
Da Nang 24
Milan 23
Dong Ket 22
Haiphong 22
Düsseldorf 20
Jinan 20
Changsha 19
Tokyo 19
Ancona 18
Frankfurt am Main 18
Orange 18
Warsaw 18
Brussels 17
Seoul 17
Baghdad 16
Belo Horizonte 16
Helsinki 16
Washington 16
Bellante 15
Guangzhou 15
Guayaquil 15
Montreal 15
Turku 15
Amsterdam 14
Boston 14
Chicago 14
Denver 14
Grevenbroich 14
Lanzhou 14
Phoenix 14
Vinh 14
Ankara 13
London 13
Nuremberg 13
Mumbai 12
Orem 12
Seattle 12
Charlotte 11
Fuzhou 11
Stockholm 11
Atlanta 10
Falls Church 10
Guadalajara 10
Johannesburg 10
Poplar 10
Rio de Janeiro 10
Brasília 9
Cepagatti 9
Changchun 9
San Francisco 9
Totale 10.755
Salva come PNG Salva come JPEG
Nome #
Il tempo di transito oro-cecale (TTOC) è accelerato dopo somministrazione orale di allergene alimentare nei pazienti con sindrome del colon irritabile (SCI) e prick test positivo 403
EFFICACY OF TREATMENT WITH PYLERA IN COMBINATION WITH RANITIDINE ON FIRST-LINE INFECTION HELICOBACTER PYLORI: EXPERIENCE OF A SINGLE CENTER 204
A Triple and Quadruple Therapy with Doxycycline and Bismuth for First-Line Treatment of Helicobacter pylori Infection: A Pilot Study 184
Ottimizzazione di vedolizumab in RCU con perdita di risposta a infliximab 172
48-Hour continuous pH measurement in patients with gastro-oesophageal reflux: effect of cisapride. 170
Beneficial effects of SR140333, a novel substance P antagonist, in a rat model of experimental colitis 169
SYMPTOM PATTERN IN FUNCTIONAL DYSPEPSIA AND GASTROESOPHAGEAL REFLUX DISEASE: ROLE OF H. PYLORI INFECTION 166
Blood cardioplegia: could it protect the ischemic-reperfused human myocardium through antioxidant-type mechanisms? 161
24-hour pancolonic motility using a portable electronic probe in healthy subjects 159
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy 159
Detection of Helicobacter pylori in the gastrointestinal tract of Balb/C euthymic mice infected by human Helicobacter pylori and evidence for transmission 155
Alterazioni non litiasiche del contenuto colecistico 150
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.Am. J. Gastroenterol 150
Two weeks regimen with amoxillicin, tinidazole and omeprazole eradicates helicobacter pylori and cures active duodenal ulcer 149
SR140333, a substance P receptor antagonist, influences morphological and motor changes in rat experimental colitis 146
Alterazioni contrattili della muscolatura liscia nel corso di colite sperimentale sono ridotte da un antagonista specifico della sostanza P 142
Anal canal diameters and pessure measured simultaneously by real time ultrasonography and manometry in human subjects 139
COMBINED VIDEOCAPSULE ENDOSCOPY (VCE) AND LACTULOSE HYDROGEN BREATH TEST (LHBT): A COMPARATIVE STUDY TO ASSESS ORO-CECAL TRANSIT TIME (OCTT). 139
Correlation between anal canal size and anal canal pressure: an ultrasonografhip and manometric study 138
Trasmissione di Helicobacter pylori in un modello murino 138
FUSOBACTERIUM NUCLEATUM (FN) IN PATIENTS AFFECTED BY INFLAMMATORY BOWEL DISEASE 136
Helicobacter pylori isolates from proximal and distal stomach of patients never treated and already treated show genetic variability and discordant antibiotic resistance. 134
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD) 134
Diameters and pressures of the anal canal simultaneously measured with endosonography and manometry 132
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC) 132
ESOPHAGITIS AND ITS CAUSES: WHO IS "GUILTY" WHEN ACID IS FOUND "NOT GUILTY"? 131
THE INFLUENCE OF ACID REFLUX ON THE HEART RATE VARIABILITY (HRV) IN PATIENTS WITH AND WITHOUT GASTROESOPHAGEAL REFLUX DISEASE (GERD). 129
EVALUATION OF INTRAPARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND LIVER STIFFNESS BY FIBROSCAN IN NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CHRONIC HEPATITIS C (CHC). 129
PRUCALOPRIDE ACCELERATES GASTRIC AND SMALL BOWEL TRANSIT TIMES OF VIDEOCAPSULES ENDOSCOPY 127
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 126
Morphological and motor changes during experimental colits in rats are prevented by a specific substance p antagonist 126
ITALIAN REAL-LIFE STUDY EVALUATING THE LONG-TERM EFFECTIVENESS OF VEDOLIZUMAB FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE: THE ELDERLY COHORT 125
Treatment of Helicobacter pylori (Hp) infection with an association of Omeprazole and Roxytromicine: a study in vivo and in vitro. 124
Distribuzione transmurale dei sistemi antiossidanti e della perossidazione lipidica nel ventricolo sinistro di coniglio 124
Pharyngeal, Esophageal and Gastric Motility in Normal Subjects and in patients with gastroesophageal Reflux Disease 123
Role of antimicrobial susceptibility testing on efficacy of triple therapy in Helicobacter pylori eradication. 122
Detection of Helicobacter pylori in esophagus and saliva in humans 122
USO DI GOLIMUMAB COME SECONDA LINEA BIOLOGICA IN UN PAZIENTE CON RETTOCOLITE ULCEROSA 122
Short- and long-term omeplazole for the tratment and prevention of duodenal ulcer, and effect on helicobacter pylori 121
MIGRATING MOTOR COMPLEX RECORDED SPONTANEOUSLY AND INDUCED BY MOTILIN AND ERYTHROMYCIN IN AN EX VIVO RABBIT INTESTINAL PREPARATION 121
A “REAL LIVE” EXPERIENCE OF INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 120
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE (IG-IBD). 120
5-HT1-RECEPTOR AGONIST SUMATRIPTAN MODIFIES GASTRIC SIZE AFTER 500 ML OF WATER IN DYSPEPTIC PATIENTS AND NORMAL SUBJECTS 119
CAN HELICOBACTER PYLORI INFECTION HAVE A ROLE ON CLINICAL APPEARANCE OF GERD? 118
Effects of cimetropium bromide on gallbladder contraction in response to oral and intraduodenal olive oil. 118
H2-RECEPTOR ANTAGONISTS ARE SCAVENGERS OF OXYGEN RADICALS 117
Erythromycin accellerates gastric and gallbladder emptying through a cholinergic mediated mechanism in humans 117
Swallows, oesophageal and gastric motility in normal subjects and in patients with gastro-oesophageal reflux disease: a 24-h-pH-manometric study 116
Transmission of Helicobacter pylori in an animal model. 116
Oesophageal and gastric motility in patients with gastro-oesophageal reflux disease 114
EVALUATION OF LIVER BLOOD FLOW AND FIBROSIS IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND CIRRHOSIS IN COMPARISON WITH NORMAL CONTROLS THROUGH CONTRAST ENHANCED ULTRASOUND(CEUS) AND FIBROSCAN 114
Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients 114
Gastric antral and fundus receptive relaxation in dyspeptic patients and normal subjects 113
PRUCALOPRIDE INCREASES BASAL LES TONE IN PATIENTS WITH ESOPHAGEAL MOTILITY DISORDERS 113
TYPICAL AND ATYPICAL SYMPTOMS OF GASTRO ESOPHAGEAL REFLUX DISEASE: DOES Helicobacter pylori MATTER? 113
Effect of omeprazole, clarithromicin and amoxicillin for a short time on helicobacter pylori eradication 112
Evidence for an oro-fecal transmission inan experimental murine model of helicobacter pylori infection. 112
Esophageal and gastric motility in patients with gastroesophageal reflux disease 111
EFFECT OF CIMETROPIUM BROMIDE ON GALLBLADDER CONTRACTION IN RESPONSE TO ORAL AND INTRADUODENAL OLIVE OIL 111
CLINICAL AND ECONOMIC IMPACT OF INFLIXIMAB ONE-HOUR INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTER STUDY 111
EFFICACY AND SAFETY OF LONG-TERM INFLIXIMAB USE FOR CROHN’S DISEASE IN SOUTHERN ITALY 110
ESOPHAGEAL MOTILITY ASSESSMENT AFTER PRUCALOPRIDE ADMINISTRATION IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY (IEM) AND SYSTEMIC SCLEROSIS. 110
Prolonged anal sphincter manometry in normal human subjects 109
Distensione gastrica nei soggetti normali e nei pazienti dispeptici helicobacter pylori positivi e negativi e correlazione con i sintomi 109
Effect of glyceryl trinitrate ointment (GTO) 0.2% and 2% on anal canal pressure during acute and chronic application in patients with anal fissure 107
Peppermint oil (Mintoil®) in the treatment or irritable bowel syndrome: a prospective double blind placebo controlled randomized trial. 107
RISPOSTA CLINICA E GUARIGIONE DELLA MUCOSA DOPO 4 ANNI DI TERAPIA CON INFLIXIMAB IN UN PAZIENTE CON MALATTIA DI CROHN ILEALE STEROIDO-RESISTENTE 107
Role of transient lower esophageal sphincter relaxations in the genesis of priximal gastro-esophageal reflux 106
SHORT AND LONG TERM EFFICACY OF GLYCERYL TRINITRATE (GTN) OINTMENT 0.2% AND 2% ON ANAL CANAL PRESSURE IN PATIENTS WITH CHRONIC ANAL FISSURES. 106
TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS AND GASTRO-ESOPHAGEAL REFLUX EPISODES IN HEALTHY SUBJECTS AND GERD PATIENTS DURING 24 HOURS 106
ULTRASOUND(US) GRADED HEPATOSTEATOSIS ASSESSMENT THROUGH CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSCAN IN NON ALCOHOLIC FATTY LIVER DISEASE 106
Registrazione delle 24 ore della motilità del piloro in soggetti normali 105
EFFECT OF THE 5-HT3 RECEPTOR ANTAGONIST, ONDANSETRON, ON GASTRIC SIZE IN DYSPEPTIC PATIENTS WITH IMPAIRED GASTRIC ACCOMODATION 105
THERAPY- RELATED ADVERS EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 105
CLINICAL AND ECONOMIC EFFECT OF SHORT INFLIXIMAB INFUSION PROTOCOL IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A MULTICENTRE STUDY 105
EFFICACIA E SICUREZZA DEL RITRATTAMENTO CON INFLIXIMAB IN UN PAZIENTE AFFETTO DA MORBO DI CROHN 104
DISORDINI MOTORI ASPECIFICI DELL’ESOFAGO 104
Increase of swallows before the onset of phase III of migrating motor complex in normal human subjects 104
SPONTANEOUS OPENING OF LES IN ACHALASIA: AN UNCOMMON ON-LINE DOCUMENTATION BY HIGH-RESOLUTION MANOMETRY 104
FPSE-HPLC-PDA METHOD FOR THE DETERMINATION OF INFLAMMATORY BOWEL DISEASE TREATMENT DRUGS IN WHOLE BLOOD, PLASMA AND URINE 104
THERAPY-RELATED ADVERSE EVENTS IN CROHN’S DISEASE (CD) – A COMPARISON BETWEEN THIOPURINES, INFLIXIMAB AND COMBINED THERAPY 103
REAL-LIFE STUDY (GORE-UC) EVALUATING THE EFFECTIVENESS OF GOLIMUMAB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN INTERIM ANALYSIS FROM ITALIAN GROUP FOR THE STUDY OF INFLAMAMTORY BOWEL DISEASE (IG-IBD). 103
EFFECT OF AN ACUTE INTRALUMINAL ADMINISTRATION OF CAPSAICIN ON OESOPHAGEAL MOTOR PATTERN IN GORD PATIENTS WITH INEFFECTIVE OESOPHAGAL MOTILITY 102
EFFECT OF CLEBOPRIDE ON ESOPHAGEAL MOTOR FUNCTION IN GERD PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY: EVALUATION USING HIGH RESOLUTION MANOMETRY 102
GRAVIDANZA IN UNA PAZIENTE AFFETTA DA RETTOCOLITE ULCEROSA IN TERAPIA CON INFLIXIMAB: CASO CLINICO 101
Gastric antral and fundic distention evaluated by ultrasonography (US) in normal subjects and patients with idiopathic dyspepsia 100
I RILASCIAMENTI TRANSITORI DELLO SFINTERE ESOFAGEO INFERIORE NELLA GENESI DEI REFLUSSI GASTRO-ESOFAGEI: PROSPETTIVE TERAPEUTICHE 100
SAFETY OF INFLIXIMAB(IFX) ONE-HOUR INFUSION IN INFLAMMATORY BOWEL DISEASE(IBD): A MULTICENTER STUDY FROM SOUTHERN ITALY 100
EVALUATION OF INTRA PARENCHYMAL AND PORTAL BLOOD FLOW BY CONTRAST ENHANCED ULTRASOUND (CEUS) AND FIBROSIS BY FIBROSCAN IN PATIENTS WITH NON ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON ALCOHOLIC STEATOHEPATITIS (NASH) AND COMPARISON WITH NORMAL CONTROLS 100
LA MALATTIA DA REFLUSSO GASTROESOFAGEO 100
Proximal and Distal Gastric Distension in Normal Subjects and H.pylori-Positive and -Negative Dyspeptic Patients and Correlation with Symptoms 99
LA MALDIGESTIONE 99
EFFECT OF HYOSCINE N-BUTYLBROMIDE ON GASTROESOPHAGEAL REFLUX IN NORMAL SUBJECTS AND PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE. 99
Role of nitric oxide on peristaltic motor activity in an in vitro rabbit intestinal preparation 99
Relationship between interdigestive esophageal and gastric motility in humans 99
ROLE OF PRUCALOPRIDE (RESOLOR) IN THE SETTING-UP OF PILLCAM COLON-CAPSULE ENDOSCOPY (CCE). EXPERIENCEFROM A SINGLE CENTRE 99
Fabric Phase Sorptive Extraction-High Performance Liquid Chromatography-Photo Diode Array Detection Method for Simultaneous Monitoring of Three Inflammatory Bowel Disease Treatment Drugs in Whole Blood, Plasma and Urine 99
ON THE SPECIFICITY OF ALTERED MUSCLE FUNCTION IN EXPERIMENTAL COLITIS IN RATS 98
EFFECT OF THE 5-HT1 AGONIST SUMATRIPTAN ON ESOPHAGEAL MOTOR PATTERN IN PATIENTS WITH INEFFECTIVE ESOPHAGEAL MOTILITY 98
EFFICACY AND SAFETY OF INFLIXIMAB IN THE LONG-TERM IN CROHN’S DISEASE 98
Totale 12.353
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.716
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 63.716
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021238 0 0 0 0 0 0 0 0 0 135 21 82
2021/2022789 35 15 4 200 46 16 24 66 54 9 88 232
2022/20232.154 188 207 108 264 194 488 145 158 253 41 59 49
2023/20241.002 79 51 62 36 34 292 236 37 14 44 19 98
2024/20252.576 182 423 292 47 54 66 99 173 310 121 252 557
2025/20264.818 488 252 637 543 453 328 787 407 577 346 0 0
Totale 18.387